CDMOP - (Avid Bioservices Inc.)

 CDMOPのチャート


 CDMOPの企業情報

symbol CDMOP
会社名
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種   
概要 事業概要 --     
本社所在地 --
代表者氏名
代表者役職名
電話番号
設立年月日 --
市場名 --
ipoyear ―年
従業員数 -
url
nasdaq_url https://www.nasdaq.com/symbol/cdmop
adr_tso
EBITDA EBITDA ー
終値(lastsale) 26.6693
時価総額(marketcap) 18668510
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 CDMOPのテクニカル分析


 CDMOPのニュース

   Avid Bioservices, Inc. Announces Proposed $125 Million Offering of Exchangeable Senior Notes - Stocks News Feed  2021/03/08 22:01:00 Stocks News Feed
TUSTIN, Calif., March 08, 2021 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (the “company”), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that its wholly-owned subsidiary, Avid SPV, LLC (the “Issuer”), intends to… Read More »Avid Bioservices, Inc. Announces Proposed $125 Million Offering of Exchangeable Senior Notes
   Humanigen and Avid Bioservices Enter Into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing  2021/02/03 12:00:00 Business Wire
BURLINGAME, Calif. & TUSTIN, Calif.--(BUSINESS WIRE)--Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (“Avid”) and Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”) today announced that they have entered into a manufacturing services agreement to expand production capacity for lenzilumab™, Humanigen’s therapeutic candidate in development for COVID-19. Lenzilumab is an anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody designed to prevent and treat an immune h
   Avid Bioservices Announces Closing of Public Offering of Common Stock  2020/12/14 21:05:00 GlobeNewswire
TUSTIN, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and…
   Avid Bioservices Announces Appointment of Jeanne Thoma to Board of Directors - Stocks News Feed  2020/12/07 21:05:00 Stocks News Feed
TUSTIN, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Jeanne Thoma as an independent member of the company’s board… Read More »Avid Bioservices Announces Appointment of Jeanne Thoma to Board of Directors
   Avid Bioservices, Inc. (CDMO) Q2 2021 Earnings Call Transcript  2020/12/03 01:11:02 AlphaStreet
Avid Bioservices, Inc. (NASDAQ: CDMO) Q2 2021 earnings call dated Dec. 02, 2020 Corporate Participants: Tim Brons — Investor Relations Nicholas Green — President and Chief Executive Officer Daniel Hart — Chief Financial Officer Timothy Compton — Chief […]

 関連キーワード  (― 米国株 CDMOP Avid Bioservices Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)